Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biology

Cancer Research

Volumn 67, Issue 2, 2007, Pages 546-554

  Kim, Yun Jeong ^a   Ahn, Ji Yeon ^a   Liang, Ping ^a   Ip, Clement ^a   Zhang, Yuesheng ^a   Park, Young Mee ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN; NUCLEAR PROTEIN; PEROXIREDOXIN; PEROXIREDOXIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIOXIDANT ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REOXYGENATION; STEADY STATE; TRANSACTIVATION; UPREGULATION;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL NUCLEUS; CLONING, MOLECULAR; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSFECTION; UP-REGULATION;

EID: 33846703755     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2401     Document Type: Article

References (50)

1. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2001;52:35-41.
2. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003;28:32-40.
3. Rabilloud T, Heller M, Gasnier F, et al. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 2002;277:19396-401.
4. Jang HH, Lee KO, Chi YH, et al. Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 2004;117:625-35.
5. 2-induced cell death. J Biol Chem 2005;280:28775-84.
6. Ishii T, Yamada M, Sato H, et al. Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J Biol Chem 1993;268:18633-6.
7. Kawai S, Takeshita S, Okazaki M, Kikuno R, Kudo A, Amann E. Cloning and characterization of OSF-3, a new member of the MER5 family, expressed in mouse osteoblastic cells. J Biochem (Tokyo) 1994;115:641-3.
8. Shau H, Kim A. Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. Biochem Biophys Res Commun 1994;199:83-8.
9. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003;424:561-5.
10. Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997;11:2456-67.
11. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 2002;277:43175-84.
12. Jung H, Kim T, Chae HZ, Kim KT, Ha H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J Biol Chem 2001;276:15504-10.
13. Yanagawa T, Ishikawa T, Ishii T, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999;145:127-32.
14. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000;156:27-35.
15. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 2001;21:2085-90.
16. Chang JW, Jeon HB, Lee JH, et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 2001;289:507-12.
17. Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004;111:514-21.
18. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005;579:2873-7.
19. 2-terminal kinase complex. Cancer Res 2006;66:7136-42.
20. Chen MF, Keng PC, Shau H, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 2006;64:581-91.
21. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
22. Greco O, Marples B, Joiner MC, Scott SD. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003;197:312-25.
23. Zander R, Vaupel P. Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol 1985;191:965-70.
24. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
25. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6.
26. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-8.
27. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
28. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998;8:143-50.
29. Klein-Szanto AJ, Iizasa T, Momiki S, et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci U S A 1992;89:6693-7.
30. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 2004;101:2040-5.
31. Park SY, Kim YJ, Gao AC, et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006;66:5121-9.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
33. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998;23:403-5.
34. Bailey TL, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 1994;2:28-36.
35. Berezikov E, Guryev V, Plasterk RH, Cuppen E. CONREAL: conserved regulatory elements anchored alignment algorithm for identification of transcription factor binding sites by phylogenetic footprinting. Genome Res 2004;14:170-8.
36. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003;43:233-60.
37. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000;275:16023-9.
38. Kang KW, Lee SJ, Park JW, Kim SG. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 2002;62:1001-10.
39. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86.
40. Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-92.
41. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 2002;3:481-90.
42. Velichkova M, Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 2005;25:4501-13.
43. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003;23:8137-51.
44. Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 2005;280:32485-92.
45. Kong AN, Owuor E, Yu R, et al. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001;33:255-71.
46. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002;277:42769-74.
47. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 2003;285:C334-42.
48. Nguyen T, Yang CS, Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 2004;37:433-41.
49. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21:689-700.
50. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional Keap1-2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:1-12.